Evidence map›Paper›PMID 41176729›Full record

ArticleCancer medicine2025

The Impact of Multidisciplinary Team Meetings on the Survival of Stage IV NSCLC Patients.

Zhengyang Lu, Nan Zhang, Qian Gao, Pengfei Li, Weimin Guan, Shihong Lin, Wenxuan Yan, Boyu Liu, Youhua Lu, Jinming Yu

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Zhengyang LuSchool of Public Health, Shandong Second Medical University, Weifang, China.ORCID https://orcid.org/0009-0008-1478-6741
Nan ZhangCancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital), Jinan, China.ORCID https://orcid.org/0000-0003-3494-5806
Qian GaoSchool of Public Health, Shandong Second Medical University, Weifang, China.ORCID https://orcid.org/0000-0001-7002-6319
Pengfei LiSchool of Public Health, Shandong Second Medical University, Weifang, China.ORCID https://orcid.org/0000-0001-9935-616X
Weimin GuanSchool of Public Health, Shandong Second Medical University, Weifang, China.ORCID https://orcid.org/0009-0006-3711-4441
Shihong LinSchool of Public Health, Shandong Second Medical University, Weifang, China.
Wenxuan YanSchool of Public Health, Shandong Second Medical University, Weifang, China.
Boyu LiuSchool of Public Health Administration, Shandong First Medical University & Shandong Academy of Medical Science, Jinan, China.
Youhua LuCancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital), Jinan, China.
Jinming YuCancer Hospital of Shandong First Medical University (Shandong Cancer Institute, Shandong Cancer Hospital), Jinan, China.

Funding

Health Commission of Shandong Province WZY202374
6 · The paper itself

Abstract

backgroundWith treatment strategies for cancer constantly evolving, the multidisciplinary team (MDT) plays a key role in optimizing cancer care, but its real-world impact on survival remains unclear. This study aims to examine the impact of MDT on overall survival (OS) among patients with stage IV non-small cell lung cancer (NSCLC), based on real-world data including all eligible patients.

methodPatients with stage IV NSCLC who were admitted for the first time to Shandong Cancer Hospital from January 1, 2021 to December 31, 2021 were divided into MDT group and non-MDT group according to MDT meeting involvement. Follow-up period extended from January 1, 2021, to May 31, 2024. Kaplan-Meier curves and log-rank tests were used to analyze survival differences, while Cox proportional hazards models were employed to identify factors associated with overall survival.

resultOne thousand six hundred and sixty-four patients were included. No statistical differences were found between the MDT group (n = 1238) and the Non-MDT group (n = 426) in baseline characteristics, but differences were observed in treatment modalities. The MDT group exhibited a longer median overall survival compared to the Non-MDT group (26.25 vs. 21.42 months; log-rank χ

conclusionMDT can effectively reduce mortality risk. Future implementation requires recognizing its potential additional benefits and developing tailored strategies.

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsPatient Care TeamAgedFemaleFollow-Up StudiesHumansKaplan-Meier EstimateMaleMiddle AgedNeoplasm StagingRetrospective StudiesTime FactorsTreatment Outcomemultidisciplinary teammultidisciplinary team meetingsnon‐small cell lung cancersurvival

Identifiers

PMID41176729
PMCPMC12579824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.